This processes is targeted for therapeutic intervention by the monoclonal antibodies ecolocumab and alicrocumab, both approved for the treatment of hypercholesterolemia.17,18 The second is IDOL, a target gene of LXRs, which are activated by oxysterol ligands under high cellular sterol conditions. The gene discussed is MYLIP; the disease is familial hypercholesterolemia.